What Faster Pharmacokinetics Mean for Detecting Small Brain Metastases

In a randomized study comparing dosing strategies of the high-relaxivity contrast agent gadopiclenol for detecting brain metastases prior to stereotactic radiosurgery, imaging was performed with a delay of roughly 13 minutes after contrast administration. Within that delayed imaging framework, patients received either a single dose of gadopiclenol or an additional off-label dose, resulting in a delayed double dose, before the follow-up scan.

In an interview with CancerNetwork® at the 2026 SNO/ASCO CNS Metastases Conference, Josef Vymazal, MD, head of the Department of Radiology and deputy director for Science and Research at Faculty Hospital Motol and Homolka, and a full professor at Charles University in Prague, Czech Republic, discussed what it meant that the delayed double-dose protocol detected significantly more lesions than standard imaging, while the delayed single-dose protocol did not produce the same improvement. Vymazal proposed that this pattern points to a pharmacokinetic difference specific to gadopiclenol, suggesting that its contrast enhancement builds more quickly after administration compared with other agents. That property that may explain why adding a second dose within the delayed imaging window meaningfully improved lesion detection when a single dose alone, even with the same delay, did not.

Vymazal also addressed the practical tradeoff this protocol requires of patients, who must sign a separate informed consent form for the off-label double dose. He argued that for patients with serious, potentially life-threatening brain disease, the clinical benefit of detecting additional metastatic lesions outweighs the modestly higher gadolinium exposure associated with the extra dose.

Transcript:

CancerNetwork: The double dose delayed protocol detected more lesions than standard imaging, while the single dose delayed protocol didn’t. What does that tell you about what’s driving the improved detection?

Vymazal: It tells us that the pharmacokinetics of this contrast agent are probably a bit different from other contrast agents, that the increase in contrast enhancement after application of the contrast agent is probably faster in comparison with other contrast agents. Practically, it tells us that if the patient signs a special informed consent form for off-label use of a double dose of contrast agent, that the patient may benefit from the exam because we are able to detect more lesions. I think that the benefit for the patient in this case is more important than the limited, higher burden of gadolinium for this person who is really sick…. The patient really needs to have all [their] brain metastasis treated.

Reference

Vymazal J, Ryznarova Z, Keller J, Liscak R, Rulseh A. Comparison of delayed and double-dose MRI for detection of brain metastases with gadopiclenol prior to stereotactic radiosurgery. Neurooncol Adv. 2026;8(Suppl 6):vdag161.062. doi:10.1093/noajnl/vdag161.062